Filter:
On Friday, April 17, 2026, the Alpha-1 Foundation (A1F) hosted the 29th Gordon L. Snider Critical Issues (GLS) Workshop: “Alpha-1 Foundation […]
April 25, 2026 marks the ninth annual European Alpha-1 Awareness Day led by the Alpha-1 Europe Alliance, a date in which those afflicted with […]
The Alpha-1 Foundation (A1F) joined the 95 undersigned organizations, including patient advocacy groups, professional scientific and medical societies are profoundly […]
Read More… from A1F joins Research Community in Strongly Opposing Proposed Cuts to NIH
The Alpha-1 Foundation (A1F) is proud to provide a monthly list of articles from researchers that have been funded by […]
It is with great sadness that we share the news that longtime Alpha-1 Foundation (A1F) supporter and AlphaNet coordinator Deborah (Debbie) LaBud […]
Read More… from The Alpha-1 Foundation Mourns the Loss of Alpha Deborah LaBud
Alpha-1 family members, friends, and caregivers from across the country came together for a meaningful and memorable Alpha-1 Foundation (A1F) Building Friends […]
Read More… from A1F Building Friends for a Cure Training: A Weekend of Growing Together
FOR IMMEDIATE RELEASE: Beam Therapeutics announced compelling updated clinical data from the ongoing Phase 1/2 trial of BEAM-302 in Alpha-1 […]
Read More… from Beam Therapeutics Announces Update on BEAM-302
Happy St. Patrick’s Day! The Alpha-1 Foundation has been celebrating St. Patrick’s Day as a community since 2008. Over 300 guests joined together […]
Each year the Alpha-1 Foundation (A1F) awards Alpha-1 Educational Scholarships to Alphas and family members seeking to further their higher […]
Dr. James K. Stoller, a nationally recognized leader in Alpha-1 Antitrypsin Deficiency (Alpha-1), has published a new article in the […]
Read More… from Alpha-1 antitrypsin deficiency: A persistently underrecognized condition
A1F Board Chair Jon Hagstrom shares with the Critical Path Institute (C-Path) how his Alpha-1 journey is informing research and […]
Every February, the rare disease community comes together with a shared purpose: to raise awareness, inspire action, and amplify the […]
The Alpha-1 Foundation (A1F) is proud to provide a monthly list of articles from researchers that have been funded by […]
As you might have seen, CMS announced the next 15 drugs to go through the Medicare Drug Price Negotiation Program in late […]
Read More… from Medicare Drug Price Negotiation Program Engagement Opportunities
“The continuation of achieving our goals hinges on detecting, testing, finding and helping every Alpha. We have increased our efforts […]
FDA NEWS RELEASE The U.S. Food and Drug Administration today issued draft guidance for sponsors seeking approval for targeted individualized […]
“We are thrilled with Wave Life Sciences commitment to the Alpha-1 patient community. Their acceleration of regulatory engagement of the […]
The Alpha-1 Foundation is proud to provide a monthly list of articles from researchers that have been funded by the […]
PRESS RELEASE SOMERVILLE, Mass., January 12, 2026 /GLOBE NEWSWIRE/ Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic […]
The Alpha-1 Foundation is proud to provide a monthly list of articles from researchers that have been funded by the […]
The second Latin American Alfa-1 Meeting titled “Consolidando avances, ampliando horizontes”, (“Consolidating Advances, Expanding Horizons”) was held on December 10, 2025, in Buenos Aires, Argentina. Organized by Alfa1 Argentina and supported by […]
Empowering Voices. Inspiring Action. Elevating Patient-Centered Work. […]
Read More… from Launch of the A1F Fred C. Walsh Speaker Bureau
A1F’s role as the global leader among the world’s Alpha-1 community was highlighted recently at an Alpha-1 Awareness Month Recognition […]
Read More… from Alpha-1 Foundation: Rationale for EU Strategic Engagement
“Thank you to the Alpha-1 patients that participated in this important clinical trial, InnovAATe. It is because of the dedication of patients […]
Read More… from Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial
